European journal of cancer (Oxford, England : 1990) · 2024
Alectinib for the treatment of papillary thyroid carcinoma harbouring STRN - ALK fusion.
СтатьяКлинический случайНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Buriolla Silvia, Zapelloni Giulia, Cipri Claudia, Pelizzari Giacomo, Follador Alessandro, Cortiula Francesco
Аннотация
BACKGROUND: Anaplastic Lymphoma Kinase (ALK) rearrangement is a rare alteration in differentiated thyroid carcinomas (DTCs). Due to its low prevalence, a few evidence are available about the use of ALK inhibitors in advanced DTCs.
METHODS: We report the case of a striatin (STRN) - ALK translocated advanced thyroid carcinoma. STRN - ALK translocation was detected by NGS - RNA analysis.
RESULTS: A 74-year-old woman received first line alectinib for the treatment of a STRN - ALK translocated advanced thyroid carcinoma with symptomatic bilateral lung localizations. The dose of alectinib was progressively reduced due to the toxicity, but the treatment is still ongoing after 17 months with complete radiological response and clinical benefit.
CONCLUSION: Here we report the first case in Europe of STRN - ALK translocated advanced thyroid carcinoma successfully treated with alectinib.
METHODS: We report the case of a striatin (STRN) - ALK translocated advanced thyroid carcinoma. STRN - ALK translocation was detected by NGS - RNA analysis.
RESULTS: A 74-year-old woman received first line alectinib for the treatment of a STRN - ALK translocated advanced thyroid carcinoma with symptomatic bilateral lung localizations. The dose of alectinib was progressively reduced due to the toxicity, but the treatment is still ongoing after 17 months with complete radiological response and clinical benefit.
CONCLUSION: Here we report the first case in Europe of STRN - ALK translocated advanced thyroid carcinoma successfully treated with alectinib.